

APPLICANTS: STEINER, Mitchell S. et al.
SERIAL NO.: 09/449,817
FILED: November 26, 1999
Page 3

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned **"Version with markings to show changes made"**.


In the Office Action, the Examiner noted that SEQ ID NOs: 1-7 are found in the claims although the instant CRF contains only 6 sequences. In response, claims 2, 3, 4, 5, 6, 8, and 9 have been cancelled without prejudice or disclaimer. Applicants assert that new claims 53 - 59 provide the correction requested by the Examiner. Applicants assert that claims 2, 3, 4, 5, 6, 8, and 9 have been cancelled and new claims 53-59 have been added to correct typographical and clerical errors of the sequences, and to clear up any matter of form.

In addition, in the Office Action, the Examiner requested that a substitute computer readable form (CRF) of the Sequence Listing, and a substitute paper copy of the Sequence Listing as well as a statement as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d) be submitted with this response.

In response, Applicants submit herewith a copy of the Notice to Comply; and the Sequence Listing on a paper and computer readable format in compliance with the requirements of 1.821 through 1.825. The computer readable form containing the nucleic acid and/or amino acid sequences as required by 37 C.F.R. 1.821(f) contains the same information which is submitted as Sequence Listing, the Sequence Listing complies with the requirements of 38 C.F.R. 1.824 and does not contain any new matter. Further, Applicants have hereinabove amended the Specification in order to conform the Specification to the Sequence I.D. Listing. Thus, Applicants Specification is in compliance with 37 C.F.R. 1.821 through 1.825. Therefore, Applicants respectfully request the Examiner to reconsider and withdraw the objection.

APPLICANTS: STEINER, Mitchell S. et al.
SERIAL NO.: 09/449,817
FILED: November 26, 1999
Page 4

If the Examiner wishes to discuss any aspect of this response, or has any suggestions and extant issues, the Examiner is encouraged to telephone the undersigned. If any additional fee is due, the undersigned Attorney hereby authorizes the United States Patent and Trademark Office to charge such fee to Deposit Account No. 05-0649.

Respectfully submitted,


Mark S. Cohen
Attorney for Applicant(s)
Registration No. 42,425

Dated: August 13, 2001

Eitan, Pearl, Latzer & Cohen-Zedek
One Crystal Park, Suite 210, 2011 Crystal Drive
Arlington, VA, USA 22202-3709
Telephone: (703) 486-1177
Fax: (703) 486-0800

APPLICANTS: STEINER, Mitchell S. et al.
SERIAL NO.: 09/449,817
FILED: November 26, 1999
Page 5



"Version with markings to show changes made"

In the claims:

Claims 2, 3, 4, 5, 6, 8, and 9 have been cancelled.

New claims 53 - 59 have been added, as follows:

53. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid has a nucleic acid sequence having at least 75% similarity with the nucleic acid coding sequence of SEQ ID NOs: 1 or 3.

54. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid has a nucleic acid sequence having at least 85% similarity with the nucleic acid coding sequence of SEQ ID NOs: 1 or 3.

55. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid has a nucleic acid sequence having at least 95% similarity with the nucleic acid coding sequence of SEQ ID NOs: 1 or 3.

56. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid fragment is set forth in SEQ ID NOs: 1 or 3.

57. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid fragment is set forth in SEQ ID NOs: 5 or 6.

58. (New) The isolated nucleic acid of claim 53, wherein the nucleic acid is cDNA or genomic DNA.

59. (New) The isolated nucleic acid of claim 1, wherein the nucleic acid encodes an amino acid sequence having the sequence as set forth in SEQ ID NOs: 2 or 4.